RQ Bio

$115.0M Series A

Announced: Jun 24, 2026
Sector: Biotechnology
Investors: 8

Summary

RQ Bio secured USD 115 million in Series A financing to support the clinical development of its lead influenza therapy and advance its broader infectious disease pipeline. EQT Life Sciences participated in the round alongside several new and existing investors. RQ Bio is a biotechnology company.

Investors

Frazier Life Sciences, EQT Life Sciences, Forbion, Monograph, Wellington Management, LifeArc, Oxford Science Enterprises, Oxford University Innovation